CN100381132C - Hypoglycemic Chinese medicine prepn and its production process - Google Patents
Hypoglycemic Chinese medicine prepn and its production process Download PDFInfo
- Publication number
- CN100381132C CN100381132C CNB031188613A CN03118861A CN100381132C CN 100381132 C CN100381132 C CN 100381132C CN B031188613 A CNB031188613 A CN B031188613A CN 03118861 A CN03118861 A CN 03118861A CN 100381132 C CN100381132 C CN 100381132C
- Authority
- CN
- China
- Prior art keywords
- adjuvant
- chinese medicine
- leucaena leucocephala
- blood sugar
- seed extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 65
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 15
- 230000002218 hypoglycaemic effect Effects 0.000 title description 23
- 210000004369 blood Anatomy 0.000 claims abstract description 69
- 239000008280 blood Substances 0.000 claims abstract description 69
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims abstract description 54
- 239000000284 extract Substances 0.000 claims abstract description 49
- 238000002360 preparation method Methods 0.000 claims abstract description 44
- 239000002671 adjuvant Substances 0.000 claims abstract description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 27
- 235000014593 oils and fats Nutrition 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000002775 capsule Substances 0.000 claims description 20
- -1 calculates with dry Substances 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 17
- 239000003826 tablet Substances 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 238000005325 percolation Methods 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 9
- 239000003208 petroleum Substances 0.000 claims description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
- 238000010411 cooking Methods 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000007943 implant Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 4
- 239000001569 carbon dioxide Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000000865 liniment Substances 0.000 claims description 3
- 229940040145 liniment Drugs 0.000 claims description 3
- 210000003205 muscle Anatomy 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 239000004952 Polyamide Substances 0.000 claims description 2
- 102000011759 adducin Human genes 0.000 claims description 2
- 108010076723 adducin Proteins 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 239000007922 nasal spray Substances 0.000 claims description 2
- 229940097496 nasal spray Drugs 0.000 claims description 2
- 239000011505 plaster Substances 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 240000001221 Leucaena esculenta Species 0.000 claims 23
- 238000007598 dipping method Methods 0.000 claims 6
- 240000007472 Leucaena leucocephala Species 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 18
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 15
- 201000001421 hyperglycemia Diseases 0.000 abstract description 13
- 239000002994 raw material Substances 0.000 abstract description 8
- 230000009467 reduction Effects 0.000 abstract description 5
- 238000010171 animal model Methods 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 28
- 239000008103 glucose Substances 0.000 description 28
- 238000000034 method Methods 0.000 description 27
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 150000004676 glycans Chemical class 0.000 description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 229920001282 polysaccharide Polymers 0.000 description 14
- 239000005017 polysaccharide Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 235000017709 saponins Nutrition 0.000 description 12
- 229930182490 saponin Natural products 0.000 description 11
- 150000007949 saponins Chemical class 0.000 description 11
- 208000007241 Experimental Diabetes Mellitus Diseases 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 9
- 229930003944 flavone Natural products 0.000 description 9
- 235000011949 flavones Nutrition 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 8
- 241000208340 Araliaceae Species 0.000 description 7
- 229920002527 Glycogen Polymers 0.000 description 7
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 description 7
- 229930013930 alkaloid Natural products 0.000 description 7
- 150000003797 alkaloid derivatives Chemical class 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 235000008434 ginseng Nutrition 0.000 description 7
- 229940096919 glycogen Drugs 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000009636 Huang Qi Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 235000012054 meals Nutrition 0.000 description 6
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 229940126678 chinese medicines Drugs 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 3
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 3
- 235000009815 Momordica Nutrition 0.000 description 3
- 241000218984 Momordica Species 0.000 description 3
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 3
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 229960003105 metformin Drugs 0.000 description 3
- 229940100243 oleanolic acid Drugs 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 description 3
- 229960003243 phenformin Drugs 0.000 description 3
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 3
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 241001061264 Astragalus Species 0.000 description 2
- 241000255791 Bombyx Species 0.000 description 2
- 241000190633 Cordyceps Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 239000008517 radix Trichosanthis Substances 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical group CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- BOVGTQGAOIONJV-BETUJISGSA-N 1-[(3ar,6as)-3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl]-3-(4-methylphenyl)sulfonylurea Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1C[C@H]2CCC[C@H]2C1 BOVGTQGAOIONJV-BETUJISGSA-N 0.000 description 1
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- NOESYZHRGYRDHS-ZYCCASTOSA-N 8a-l-threonine-10a-l-isoleucine-insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 NOESYZHRGYRDHS-ZYCCASTOSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000002230 Diabetic coma Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 102100036264 Glucose-6-phosphatase catalytic subunit 1 Human genes 0.000 description 1
- 101710099339 Glucose-6-phosphatase catalytic subunit 1 Proteins 0.000 description 1
- 102000005237 Isophane Insulin Human genes 0.000 description 1
- 108010081368 Isophane Insulin Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- VQEMPEOYTVVZKZ-UHFFFAOYSA-N OC([K])=O Chemical compound OC([K])=O VQEMPEOYTVVZKZ-UHFFFAOYSA-N 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000002908 adrenolytic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- FYQXODZRNSCOTR-UHFFFAOYSA-N atractyloside Natural products O1C(CO)C(OS(O)(=O)=O)C(OS(O)(=O)=O)C(OC(=O)CC(C)C)C1OC1CC2(C)C3CCC(C(=C)C4O)CC34CCC2C(C(O)=O)C1 FYQXODZRNSCOTR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000009670 cang er zi wan Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001761 chlorpropamide Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229960000346 gliclazide Drugs 0.000 description 1
- 229960001381 glipizide Drugs 0.000 description 1
- ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 1
- 230000004116 glycogenolysis Effects 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 150000002338 glycosides Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a traditional Chinese medicine preparation with the function of blood sugar reduction. In the preparation, an ingredient which performs the function of blood sugar reduction is leucaena glauca seeds or leucaena glauca extract. Leucaena glauca seeds or leucaena glauca extract is used as base raw material, medicinal adjuvant raw material is not needed, or only a proper amount of medicinal adjuvant raw material is added to the base raw material, and the present invention is prepared by means of a conventional process for preparing medicine. Experimental results of the present invention show that the traditional Chinese medicine preparation with leucaena glauca seeds as raw material has good effects on blood sugar reduction after the traditional Chinese medicine preparation is applied on animal models of hyperglycemia and patients of diabetes.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation, particularly have hypoglycemic Chinese medicine preparation.
Background technology
Diabetes are a kind of sugar, protein and lipodystrophy endocrinopathy, the serious harm body is healthy entirely, its sickness rate just is being the trend that rises year by year, the reason of onset diabetes is numerous, but main imbalance is insulin secretion or generates unusual, mid-aged population is occurred frequently, the serious threat human health.Doctor trained in Western medicine blood sugar lowering commonly used clinically mainly comprises two classes: 1. oral hypoglycemic: sulphanylureas, as chlorpropamide, glibenclamide, glipizide, gliclazide etc.; Biguanides is as phenformin, metformin etc.The effect of Western medicine oral hypoglycemic is slower, in being only applicable to, patients with mild.2. insulin type: as regular insulin, neutral protamine zinc insulin etc., be applicable to the rescue diabetic coma, can not be oral, can only inject.Insulin type is generally subcutaneous injection, and its mechanism of action can be quickened the anerobic glycolysis and the aerobic oxidation of glucose for increasing the utilization of glucose, promote the synthetic and storage of hepatic glycogen and muscle glycogen, and can promote that glucose changes fat into, suppress glycogenolysis and glyconeogenesis, thereby can blood sugar lowering.Non-insulin-dependent diabetes mellitus accounts for more than 95% in China's diabetics, this class patient symptom is lighter, and insulinize weak effect, the hypoglycemic medicine of oral chemosynthesis are its main treatment means, but this class drug side effect is big, price is high, should not take for a long time.
Along with the increasing of diabetes patient, people begin to pay attention to the medicine of exploitation blood sugar lowering from Chinese herbal medicine in recent years.Open source literature has reported that the active component of some Chinese medicines has hypoglycemic activity, as 1. momordica saponinss, extracts momordica saponins and irritate stomach for the alloxan diabetes rabbit from Fructus Momordicae charantiae, and hypoglycemic activity and glyburide are suitable and effect is lasting.Treat type ii diabetes with momordica saponins clinically, its hypoglycemic activity is obvious, and non-toxic reaction.2. ginseng polysaccharide, ginseng polypeptide, ginsenoside, blood sugar reducing component is a lot of in the Radix Ginseng.The ginseng polysaccharide all has remarkable reduction effect to experiment mice hyperglycemia and rabbit hyperglycemia, and blood sugar reducing function has obvious dose-effect relationship a little less than insulin.Ginseng polypeptide has hypoglycemic activity to the experimental hyperglycemia rat, and can prevent and treat the decomposition of epinephrine to hepatic glycogen.Stem and leaf of Radix Ginseng saponin can obviously improve serum insulin, and blood sugar lowering increases SOD content, reduces the LP0 level, also can reduce platelet aggregation rate.3. Dihuang polysaccharide, Radix Rehmanniae polysaccharide, the ethanol precipitation component (RG-WP) of Radix Rehmanniae water extract is mainly fruit acid sample polysaccharide and forms, and normal and inductive mice are had blood sugar reducing function, can also stimulate secretion of insulin and reduce the glycogen content of normal rat liver.The four polysaccharide lumbar injection alloxan diabetes rats of extracting from Radix Rehmanniae are blood sugar lowering obviously, increases hepatic glycogen content, also can reduce the G-6-Pase activity.4. oleanolic acid and Saponin thereof, oleanolic acid is water-fast triterpenoid compound, the hyperglycemia mice to normal mouse and adrenal gland, alloxan or glucose cause all has significant hypoglycemic activity.The ethanol extract of Spica Prunellae contains triterpenoid saponin, glycoside unit and oleanolic acid, can significantly reduce hepatic glycogen content in the normal mouse blood glucose, and to the experiment diabetic mice, successive administration 3 days is blood sugar lowering obviously.5. Radix Ophiopogonis polysaccharide, oral Radix Ophiopogonis polysaccharide 100 mg/kg of normal mouse, remarkable blood sugar lowering effect is arranged, 11 hours blood sugar concentrations reduce by 54% after the administration: oral 200 mg/kg of experiment diabetic mice, energy is the blood sugar lowering level obviously, administration 4～11 hours, hypoglycemic activity is the most remarkable.6. puerarin, puerarin has obvious hypoglycemic activity to mice alloxan hyperglycemia, and minimum effective dose is 250 mg/kg.Puerarin and aspirin share, and hypoglycemic activity is strong, can improve carbohydrate tolerance, and adrenal gland's disposition hyperglycemia is also had blood sugar reducing function.7. artificial cordyceps mycelia's polysaccharide, two kinds of polysaccharide CSOH that from the artificial cordyceps mycelia, extract with different process and CHWC, lumbar injection all can reduce the blood glucose of normal mouse and experiment diabetic mice.Oral CSOH has remarkable blood sugar reducing function, but oral CHWC does not then see blood sugar reducing function.8. xanthostrumarin, xanthostrumarin AA2 is a kind of toxic component that hypoglycemic activity is arranged, 1.25～5 mg/kg lumbar injections can obviously reduce normal rat blood glucose, invalid to the alloxan diabetes rat, but the hepatic glycogen to rat and mice all has obvious reduction effect, still can be to adrenolytic blood glucose increasing effect, its blood sugar lowering mechanism can be similar to phenformin.Oral or the injection of Fructus Xanthii carboxyl potassium atractylate all has remarkable blood sugar lowering effect to normal rabbits, rat, dog, and alloxan diabetes rats is also had the blood sugar lowering effect.9. Semen Coicis polysaccharide, Semen Coicis Polysaccharide A, B, C lumbar injection normal mouse all have hypoglycemic activity, and be wherein the strongest with many brans A effect.10. astragalus polysaccharides, mouse peritoneal injection astragalus polysaccharides APS, glucose load mouse blood sugar level is obviously reduced, obviously resist the blood sugar increasing that the adrenal gland causes, and hypoglycemia due to the phenformin also there is remarkable antagonism, show that the Radix Astragali has dual regulation to blood glucose, but islets of langerhans disposition hypoglycemia is not had obvious influence.11. THFPS, THFPS A, the B that extracts from RADIX TRICHOSANTHIS, C, E give the normal mouse subcutaneous injection after 7 hours, and blood glucose obviously descends, and D has hypoglycemic activity slightly in administration after 24 hours.Give the inductive hyperglycemia mouse subcutaneous injection of alloxan THFPS A after 7 hours, significant dose dependent blood sugar reducing function is arranged.12. garlicin, garlicin are a kind of sulfide that extracts in the Bulbus Allii, can significantly improve the serum insulin levels of alloxan diabetes rats, blood sugar lowering.Pathological observation also can promote islet cells propagation, and the cell endocrine granules is increased.At present, also have many Chinese medicines such as Rhizoma Polygonati, Rhizoma Dioscoreae, Fructus Ligustri Lucidi, Fructus Lycii, Cortex Lycii, the Rhizoma Anemarrhenae, Semen Litchi, Bombyx Batryticatus etc. to find to have the blood sugar lowering effect after deliberation, relevant active component wherein waits for and is disclosed.Above-mentioned these Chinese medicines are for developing and these medicines of clinical practice provide useful guide, but at present tcm development are become preparation few of blood sugar lowering, many patients are also main rely on Western medicine particularly insulin as main medicine.
Patent documentation also discloses the Chinese medicine preparation of some treatment diabetes, as Chinese patent " a kind of specific medicament for the treatment of diabetes "＜application number〉02100812, it is by Cornu Cervi Pantotrichum 15-25 Radix Trichosanthis 10-20 Rhizoma Dioscoreae 7-12 Fructus Lycii 7-12 Rhizoma Anemarrhenae 7-12 Radix Ginseng 5-9 Radix Astragali 5-9 Fructus psidii guajavae immaturus 3-7 Cortex Lycii 3-7 Radix Scrophulariae 3-7 Cortex Moutan 3-7.Be raw material, through select materials, pulverizing, uniform mixing form.＜application number〉00135772＜denomination of invention a kind of medicine for the treatment of diabetes and preparation method thereof it be to be raw material with nine flavor Chinese herbal medicine such as Radix Ophiopogonis, dagger-axe root, Radix Panacis Quinquefolii, the Cortex Eucommiae, Rhizoma Dioscoreae, according to the different qualities of every flavor Chinese medicine, make powder or capsule by processing steps such as lyophilization, processing pulverizing, ripening sterilizations respectively." the Sanxiaodan capsule and the compound methods thereof of treatment diabetes "＜application number〉98107248, the Sanxiaodan capsule that it is made by the Radix Astragali, Rhizoma Polygonati, Radix Scrophulariae, Herba Dendrobii, Poria, the Rhizoma Atractylodis Macrocephalae, Rhizoma Atractylodis, Rhizoma Dioscoreae, Radix Panacis Quinquefolii, Radix Platycodonis, Pericarpium Citri Reticulatae, Endothelium Corneum Gigeriae Galli, Radix Angelicae Sinensis, Radix Glycyrrhizae 14 flavor Chinese medicines, have the yin yang complementarity effect, be intended to replenishing QI to invigorate the spleen, hold concurrently with dissipating blood stasis." hypoglycemic medicine composition "＜application number〉97120257, the active component of said composition is the extract of Bombyx bombycis, the Radix Astragali, Herba Cistanches, Rhizoma Polygonati, Radix Salviae Miltiorrhizae, Poria Six-element Chinese medicine, this extract is to make by the method for decocting in water precipitate with ethanol." Chinese medicine and the production methods thereof of treatment diabetes "＜application number〉95103732, the main component of this Chinese medicine is animal pancreas, Fructus Momordicae charantiae, Fructus Cucurbitae moschatae, the Radix Astragali, it is dry that Rhizoma Dioscoreae, production method are that animal pancreas is pulverized, and mixes with the Fructus Momordicae charantiae that obtains with water extraction or separating out alcohol method, Fructus Cucurbitae moschatae, Radix Astragali extract to add Rhizoma Dioscoreae powder again and obtain, this medicine has supplementing QI for promoting the production of body fluid, spleen invigorating is moisturized, and nourishing YIN to lower pathogenic fire power is imitated, and the human body immunity improving function is arranged, promote insulin secretion, the blood sugar lowering effect.Said medicine also provides the foundation of the treatment by Chinese herbs diabetes of lot of valuable, have combine the back therapeutic effect with doctor trained in Western medicine better, but the medicine that has is a wild plant, quantity is few, price is higher.
Technology contents
The invention provides a kind of Chinese medicine preparation, form by seed extract and the adjuvant of Leucaena leucocephala (L.) Leucaena leucocephala (L.) with blood sugar lowering effect.The composition that wherein has hypoglycemic activity is the Leucaena leucocephala (L.) seed extract, adjuvant only play figuration, anticorrosion, compose effects such as perfume, flavoring.Said preparation can be used for treating diabetes, also can treat the hyperglycemia disease that interior some factor of body or factors such as ectocine such as gestation cause.
The composition and the weight percentage of Chinese medicine preparation of the present invention following (in dry):
Leucaena leucocephala (L.) seed or extract 0.01-100%
Adjuvant 0-99.99%
Leucaena leucocephala (L.) Leucaena leucocephala (L.) grows in the tropical and subtropical zone area, is perennial pulse family xylophyta.Wild widely distributed, the breeding from overseas introduction is also arranged.According to bibliographical information, have only leucaena leaf in animal husbandry, to be applied, be used to prepare animal feed.End up till now, the Leucaena leucocephala (L.) seed is not also listed in the Chinese crude drug standard (or catalogue) of national drug supervisory and management department approval, does not report with the open source literature that is used as medicine relevant yet.
The extract that the present invention extracts from the Leucaena leucocephala (L.) seed mainly contains compositions such as flavone compound, alkaloid, saponins.
Chinese medicine preparation adjuvant of the present invention is chosen from the pharmaceutic adjuvant of the world or China's regulation.
Experimental result of the present invention shows, is raw material with the Leucaena leucocephala (L.) seed, and therefrom the extract of Ti Quing is the effective site (or effective part group) with hypoglycemic activity; With the Chinese medicine preparation that this extract is made, use on one's body at zoic model with hyperglycemia and diabetes patient, the result shows good blood sugar decreasing effect.
The production of blood sugar lowering Chinese medicine preparation of the present invention can utilize general pharmaceutical technology (tcd) as required, produces to obtain different preparation (or dosage form): oral Preparation, as oral liquid, tablet, capsule, buccal tablet; Percutaneous drug administration preparation is as liniment, plaster; Injecting and administering preparations is as injection; The spray delivery preparation is as nasal spray, throat spray; The drug delivery implant preparation is as subcutaneous implant, muscle implant.
Blood sugar lowering Chinese medicine preparation of the present invention can the Leucaena leucocephala (L.) seed be a monarch drug, adds other Chinese medicine compatibility with it, makes Chinese traditional compound medicine.
The specific embodiment
Below be concrete production process:
1. the preparation of Leucaena leucocephala (L.) seed extract
Extracting method adopts common pharmaceutical technology and method, no matter with what method preparation, be principle all, promptly should contain one or more of following composition in the extract at least: flavone compound, alkaloid, saponins to contain blood-sugar-lowering effective parts (or effective part group) in the extract.
The Leucaena leucocephala (L.) seed can adopt dry product or bright product, but recommends to use dry product, so that store, guarantees the concordance of material quality.The Leucaena leucocephala (L.) seed is preferably removed oils and fats earlier before entering extraction process.Method: the Leucaena leucocephala (L.) seed meal is broken into coarse powder, with industrial naptha, petroleum ether, ether, organic solvent that the benzene isopolarity is little, adopts backflow, percolation or impregnating method to remove oils and fats, is equipped with thick paste or dried cream in order to the below legal system then.
Method one
Remove except that the Leucaena leucocephala (L.) seed coarse powder behind the oils and fats, decoct with water 3-4 time, merge water cooking liquid, filter, be condensed into thick paste or dried cream, its main component is flavone compound, alkaloid and saponins.
Method two
Above method one gained water cooking liquid is handled by passing through capable " decocting in water precipitate with ethanol " method in the pharmaceutical technology.As: water cooking liquid filters, and is concentrated to proportion 1.2 (80 ℃ of mensuration), presses the concentrated solution volume, adds 2 times 95% ethanol, gets supernatant after 24 hours, is condensed into thick paste or dried cream, and its main component is flavone compound, alkaloid and saponins.
Method three
Remove the Leucaena leucocephala (L.) seed coarse powder that removes behind the oils and fats, add 95% alcohol reflux 3-4 time, merge extractive liquid,, filtration is condensed into thick paste or dried cream, and its main component is flavone compound, alkaloid and saponins.
Method four
Remove except that the Leucaena leucocephala (L.) seed coarse powder behind the oils and fats, the ethanol percolation with 70% is collected the fluid of filtering, and filters, and is condensed into thick paste or dried cream, and its main component is flavone compound, alkaloid and saponins.
Method five
Remove except that the Leucaena leucocephala (L.) seed coarse powder behind the oils and fats, decoct with water 3-4 time, merge water cooking liquid, filter, filtrate behind a large amount of washing posts, is used 95% ethanol elution by polyamide chromatography post; Collect eluent, reclaim ethanol, extract obtained main component is a flavone compound.
Method six
Remove except that the Leucaena leucocephala (L.) seed coarse powder behind the oils and fats, decoct with water 3-4 time, merge water cooking liquid, filter, be concentrated into 1: 1 (ml: the g crude drug), with ethyl acetate extraction; Collect the ethyl acetate phase, reclaim ethyl acetate, extract obtained main component is flavone compound and saponins.
Method seven
Remove except that the Leucaena leucocephala (L.) seed coarse powder behind the oils and fats, with supercritical CO
2(carbon dioxide) is extraction solvent, is entrainer with ethanol, carries out carbon dioxide supercritical fluid extraction, and extract obtained main component is flavone compound and alkaloid.
2. the preparation example of blood-sugar lowering tcm drug preparation
Embodiment one
Get above extracting method one and get dry extract, pulverize, be filled directly into capsule, every capsules is equivalent to 1.5g raw medicinal herbs (Leucaena leucocephala (L.) seed).
Embodiment two
Get above extracting method three and get dry extract, add appropriate amount of starch, be pressed into tablet, the heavy 0.3g of substrate, every is equivalent to 2g raw medicinal herbs (Leucaena leucocephala (L.) seed).
Embodiment three
It is extract obtained to get above extracting method five, adds the purified water dissolving, and microporous filter divides the lyophilizing bottle of packing into, lyophilization, injection.Every bottle is equivalent to 5g raw medicinal herbs (Leucaena leucocephala (L.) seed).
Embodiment four
It is extract obtained to get above extracting method five, with an amount of 30% dissolve with ethanol, adds 1% azone and makes penetrating agent, makes the skin liniment solution that every ml contains crude drug 5g.
Embodiment five
It is extract obtained to get above extracting method five, adds an amount of crystal type sorbitol and water soluble starch, is pressed into sublingual lozenge.
Embodiment six
It is extract obtained to get above extracting method seven, is dissolved in water, and adds an amount of Tween 80 stabilizing agent, makes spray nose or throat spray.
Embodiment seven
Get the Leucaena leucocephala (L.) seed meal and be broken into fine powder,, adopt backflow, percolation or impregnating method to remove oils and fats, add appropriate amount of starch, sorbitol then, be pressed into tablet or capsule with industrial naptha, petroleum ether, ether, organic solvent that the benzene isopolarity is little.
Embodiment eight
Get the Leucaena leucocephala (L.) seed meal and be broken into powder, with industrial naptha, petroleum ether, ether, organic solvent that the benzene isopolarity is little, adopt backflow, percolation or impregnating method to remove oils and fats, add an amount of carboxymethyl starch, calcium hydrogen phosphate, sodium carboxymethyl cellulose then and other has the Chinese medicine powder of blood sugar reducing function, be pressed into tablet or capsule.
Five, pharmacodynamic action test
Use the tablet (hereinafter to be referred as " tablet ") of above example one gained capsule (hereinafter to be referred as " capsule ") and example two gained, entrust pharmacology teaching and research room of Colleges Of Traditional Chinese Medicine Of Guangxi to experimentize, the result is as follows.
1 instrument, reagent and animal
1.1 be subjected to reagent thing and reagent: be subjected to the reagent thing to provide (tablet and capsule) by Deng Jiagang; Be subjected to the reagent thing respectively to add certain solvent and grind to form desired concn for experiment usefulness.Metformin hydrochloride is sky, Guizhou peace pharmaceutcal corporation, Ltd product.The close pyridine of four oxygen is a BDH company product (Britain).Glucose is Xin Xiang chemical plant, a Guangzhou product.It is Eastern Europe, Wenzhou, Zhejiang biological engineering company limited product that serum glucose is measured test kit.
1.2 laboratory animal: NIH kind mice, body weight 20-24g, the male and female dual-purpose is provided regular grade by Colleges Of Traditional Chinese Medicine Of Guangxi's Experimental Animal Center.
1.3 instrument: 722 type grating spectrophotometers, Shanghai analytical tool three factories.
2 methods and result
2.1 influence to the alloxan diabetes mice
Get 50 normal mouse tail vein injection alloxan (72mg/kg), predict serum level of glucose behind the 72h, select for use blood glucose value to study the above person of 16mmol/L.Mice is divided into the normal control group, model group, metformin (100mg/kg) group, " capsule " group and " tablet " group.Every day, gastric infusion was 1 time, and normal control group and model group give the equal-volume distilled water, continuous 10 days.After the last administration 1 hour, get blood from the mouse orbit venous plexus, centrifuging and taking serum is measured blood sugar level with the clinical reagent box, the results are shown in Table 1.The result shows, compares with model group, and " capsule " group, " tablet " group and metformin group raise to the alloxan diabetes mouse blood sugar obvious inhibitory action is arranged, and have hypoglycemic activity.
Table 1 blood-sugar lowering tcm drug preparation to the influence of alloxan diabetes mice (X ± S, n=10)
Compare with matched group: ###P＜0.001; Compare with model group: * P＜0.05, * * P＜0.01
2.2 glucose is caused the influence of hyperglycemia mouse blood sugar
Get 50 of mices, be divided into matched group at random, model group, metformin (100mg/kg) group, " capsule " group and " tablet " group.Every day, gastric infusion was 1 time, and normal control group and model group give the equal-volume distilled water, continuous 10 days.After the last administration 1 hour, matched group ip equal-volume normal saline, all the other respectively organize ip glucose (2g/kg) solution, after behind the ip glucose 0.5,1,2 hour, from mouse orbit venous plexus measuring blood sugar of blood extracting level, the results are shown in Table 2 respectively.The result shows, with model group relatively, " capsule " group, " tablet " group and metformin group have the obvious suppression effect to the blood sugar increasing that 0.5 hour glucose behind the ip glucose causes, still have certain hypoglycemic activity in 1,2 hour, but not obvious.
Table 2 blood-sugar lowering tcm drug preparation to glucose cause the hyperglycemia mouse blood sugar influence (X ± S, n=10)
Compare with matched group: #P＜0.05, ###P＜0.001; Compare with model group: * P＜0.05, * * P＜0.01, * * * P＜0.001
3 conclusions
Experimental result shows that Chinese medicine preparation " capsule " and " tablet " raise to the alloxan diabetes mouse blood sugar obvious inhibitory action, simultaneously glucose is caused that the hyperglycemia mouse blood sugar had obvious blood sugar reducing function at 0.5 hour.
Six, toxicity test
To above example one gained capsule (hereinafter to be referred as " capsule "), entrust pharmacology teaching and research room of Colleges Of Traditional Chinese Medicine Of Guangxi to experimentize, the result shows, is subjected to the reagent thing acute toxicity not occur and long term toxicity reacts, and can not survey LD
50
Seven, clinical effectiveness
Because of the present invention does not obtain the clinical official written reply of new drug as yet, can not enter clinical research, therefore only carry out the clinical practice experiment on one's body 3 routine volunteers, clinical effectiveness all is chosen as " produce effects ".One of them example is as follows:
Osmanthus * *, the man, Nanning people from city, 54 years old, readme: the thirsty kind drink of happiness, frequent micturition, polyorexia, dysphoria with smothery sensation is breathed hard, cardiopalmus, insomnia.Control fasting glucose average 8.3mmol/L 3 times, 3 times 2 hours after the meal mean blood glucose 13.3mmol/L.Tcm diagnosis: quench one's thirst (deficiency of both QI and YIN).Western medicine diagnose: type ii diabetes.Take above example one homemade capsule, every day 3 times, each 3.Medication is the polyuria sx after 10 days, and fasting glucose is reduced to 7.8mmol/L, and blood glucose was reduced to 8.6mmol/L in 2 hours after the meal.After 1 month, " more than three " symptom disappears substantially, and fasting glucose is reduced to 6.9mmol/L, and blood glucose was reduced to 7.3mmol/L in 2 hours after the meal.Clinical therapeutic efficacy is assessed as " produce effects ".
Claims (7)
1. the production method of a blood sugar lowering Chinese medicine preparation, it is characterized in that: it is made by Leucaena leucocephala (L.) seed extract and adjuvant, calculates with dry, and its composition and weight percentage are as follows:
Leucaena leucocephala (L.) seed extract 0.01-100%;
Adjuvant 0-99.99%;
Described Leucaena leucocephala (L.) seed extract is earlier with industrial naptha, petroleum ether, ether or benzene, adopt backflow, percolation or dipping method to remove oils and fats, remove then except that the Leucaena leucocephala (L.) seed coarse powder behind the oils and fats, decoct with water 3-4 time, merge water cooking liquid, filter, be condensed into thick paste or dried cream, add adjuvant, make the blood sugar lowering Chinese medicine preparation;
Described adjuvant is the pharmaceutic adjuvant of pharmaceutically stipulating.
2. the production method of a blood sugar lowering Chinese medicine preparation, it is characterized in that: it is made by Leucaena leucocephala (L.) seed extract and adjuvant, calculates with dry, and its composition and weight percentage are as follows:
Leucaena leucocephala (L.) seed extract 0.01-100%;
Adjuvant 0-99.99%;
Described Leucaena leucocephala (L.) seed extract is earlier with industrial naptha, petroleum ether, ether or benzene, adopt backflow, percolation or dipping method to remove oils and fats, remove then except that the Leucaena leucocephala (L.) seed coarse powder behind the oils and fats, water cooking liquid filters, and proportion 1.2 when being concentrated to 80 ℃, press the concentrated solution volume, the ethanol that adds 2 times 95% was got supernatant after 24 hours, was condensed into thick paste or dried cream, add adjuvant, make the blood sugar lowering Chinese medicine preparation;
Described adjuvant is the pharmaceutic adjuvant of pharmaceutically stipulating.
3. the production method of a blood sugar lowering Chinese medicine preparation, it is characterized in that: it is made by Leucaena leucocephala (L.) seed extract and adjuvant, calculates with dry, and its composition and weight percentage are as follows:
Leucaena leucocephala (L.) seed extract 0.01-100%;
Adjuvant 0-99.99%;
Described Leucaena leucocephala (L.) seed extract is earlier with industrial naptha, petroleum ether, ether or benzene, adopt backflow, percolation or dipping method to remove oils and fats, remove then except that the Leucaena leucocephala (L.) seed coarse powder behind the oils and fats, add 95% alcohol reflux 3-4 time, merge extractive liquid, filters, and is condensed into thick paste or dried cream, add adjuvant, make the blood sugar lowering Chinese medicine preparation;
Described adjuvant is the pharmaceutic adjuvant of pharmaceutically stipulating.
4. the production method of a blood sugar lowering Chinese medicine preparation, it is characterized in that: it is made by Leucaena leucocephala (L.) seed extract and adjuvant, calculates with dry, and its composition and weight percentage are as follows:
Leucaena leucocephala (L.) seed extract 0.01-100%;
Adjuvant 0-99.99%;
Described Leucaena leucocephala (L.) seed extract is earlier with industrial naptha, petroleum ether, ether or benzene, adopt backflow, percolation or dipping method to remove oils and fats, remove then except that the Leucaena leucocephala (L.) seed coarse powder behind the oils and fats, ethanol percolation with 70%, the collection fluid of filtering is filtered, and is condensed into thick paste or dried cream, add adjuvant, make the blood sugar lowering Chinese medicine preparation;
Described adjuvant is the pharmaceutic adjuvant of pharmaceutically stipulating.
5. the production method of a blood sugar lowering Chinese medicine preparation, it is characterized in that: it is made by Leucaena leucocephala (L.) seed extract and adjuvant, calculates with dry, and its composition and weight percentage are as follows:
Leucaena leucocephala (L.) seed extract 0.01-100%;
Adjuvant 0-99.99%;
Described Leucaena leucocephala (L.) seed extract is earlier with industrial naptha, petroleum ether, ether or benzene, adopt backflow, percolation or dipping method to remove oils and fats, remove then except that the Leucaena leucocephala (L.) seed coarse powder behind the oils and fats, decoct with water 3-4 time, merge water cooking liquid, filter, filtrate is by polyamide chromatography post, behind a large amount of washing posts, use 95% ethanol elution; Collect eluent, reclaim ethanol, extract obtained adding adjuvant is made the blood sugar lowering Chinese medicine preparation;
Described adjuvant is the pharmaceutic adjuvant of pharmaceutically stipulating.
6. the production method of a blood sugar lowering Chinese medicine preparation, it is characterized in that: it is made by Leucaena leucocephala (L.) seed extract and adjuvant, calculates with dry, and its composition and weight percentage are as follows:
Leucaena leucocephala (L.) seed extract 0.01-100%;
Adjuvant 0-99.99%;
Described Leucaena leucocephala (L.) seed extract is earlier with industrial naptha, petroleum ether, ether or benzene, adopt backflow, percolation or dipping method to remove oils and fats, be extraction solvent then with the supercritical carbon dioxide, with ethanol is entrainer, carry out carbon dioxide supercritical fluid extraction, extract obtained adding adjuvant is made the blood sugar lowering Chinese medicine preparation;
Described adjuvant is the pharmaceutic adjuvant of pharmaceutically stipulating.
7. according to the production method of the arbitrary described blood sugar lowering Chinese medicine preparation of claim 1-6, it is characterized in that: described Chinese medicine preparation is oral liquid, tablet, capsule, liniment, plaster, injection, nasal spray, throat spray, subcutaneous implant or muscle implant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031188613A CN100381132C (en) | 2003-03-25 | 2003-03-25 | Hypoglycemic Chinese medicine prepn and its production process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031188613A CN100381132C (en) | 2003-03-25 | 2003-03-25 | Hypoglycemic Chinese medicine prepn and its production process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1636579A CN1636579A (en) | 2005-07-13 |
| CN100381132C true CN100381132C (en) | 2008-04-16 |
Family
ID=34842676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031188613A Expired - Fee Related CN100381132C (en) | 2003-03-25 | 2003-03-25 | Hypoglycemic Chinese medicine prepn and its production process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100381132C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0621960A2 (en) * | 2006-08-10 | 2011-12-27 | Wood One Co Ltd | hypoglycemic composition containing acacia bark derivative |
| CN101167861B (en) * | 2007-10-22 | 2011-07-20 | 天津科技大学 | A kind of hypoglycemic compound traditional Chinese medicinal liquid preparation and preparation method thereof |
| CN101897717B (en) * | 2010-05-25 | 2011-12-14 | 张艳波 | A kind of traditional Chinese medicine composition and application for treating diabetes |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001031528A (en) * | 1999-07-16 | 2001-02-06 | Mandom Corp | Hair growth agent composition |
| JP2001354523A (en) * | 2000-06-13 | 2001-12-25 | Mandom Corp | Hair restorer composition |
-
2003
- 2003-03-25 CN CNB031188613A patent/CN100381132C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001031528A (en) * | 1999-07-16 | 2001-02-06 | Mandom Corp | Hair growth agent composition |
| JP2001354523A (en) * | 2000-06-13 | 2001-12-25 | Mandom Corp | Hair restorer composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1636579A (en) | 2005-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101411760B (en) | Novel use of plants in sorbus malus group of malus | |
| CN106606529A (en) | Composition with auxiliary blood sugar reduction efficacy, and preparation method and application thereof | |
| CN102743401A (en) | Application of panaxadiol saponins fraction in preparing medicine for preventing epilepsia | |
| CN107006856A (en) | One kind enhancing endurance, raising anti anoxia tolerance nutritional agents and preparation method thereof | |
| CN101284050B (en) | Corydalis tuber water soluble part medicament and its preparation method and application | |
| CN101856405B (en) | A kind of pharmaceutical composition for treating type 2 diabetes and its preparation method | |
| CN103272125B (en) | Chinese medicine composition with blood sugar reducing function containing Herba Dendrobii and preparation method thereof | |
| CN100381132C (en) | Hypoglycemic Chinese medicine prepn and its production process | |
| CN101978963B (en) | Annonaceous acetogenin extract, preparation method thereof and use thereof in cancer resistance and relief of cancerous pain | |
| CN101953887B (en) | Medicinal composition for preventing and treating diabetic complications and preparation method thereof | |
| CN101433667A (en) | Pharmaceutical composition with function for reducing blood sugar and preparation method thereof | |
| CN103385931B (en) | Blood-sugar-lowering medicine composition | |
| CN105535070B (en) | The pharmaceutical composition and its preparation method and application for treating diabetes | |
| CN110742983B (en) | Traditional Chinese medicine preparation for treating acute gout attack and preparation method thereof | |
| CN104042928B (en) | A kind of pharmaceutical composition for treating diabetes and its production and use | |
| CN1150839C (en) | Health food with blood pressure and blood lipoid regulating function and its production process | |
| CN100528170C (en) | Mangiferin preparation and production thereof | |
| CN1318034C (en) | Drug prepared by mulberry bark extract | |
| CN102631419B (en) | Medicine composition for treating gout, as well as preparation method and application of medicine composition | |
| CN115137770A (en) | Preparation method of traditional Chinese medicine product with efficacy of reducing blood fat and blood pressure | |
| CN1315499C (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN1506079A (en) | Diabetes treating medicine | |
| CN101450174A (en) | Medicine composition with blood-sugar reduction function and preparation method thereof | |
| CN101322762B (en) | Medicinal composition for treating diabetes | |
| CN100355440C (en) | Compound Chinese medicinal preparation for treating type II diabetes and lowering blood sugar and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080416 Termination date: 20140325 |